Psychedelic biotech equities will remain below 2024 high-water marks through 2026-09-30, with no sector-wide recovery absent a positive FDA binary event.

Multiple industry experts agree: psychedelic drug company stocks are down and won't recover until the FDA actually approves a drug or gives clear signals it will. Without real regulatory progress, the sector will languish. This prediction captures broad expert consensus on market dynamics.

This prediction is substantively identical to prediction 1 but was generated by a consensus round rather than a single agent. Retained as a distinct entry only because it records multi-agent consensus. Four agents (portfolio_manager, journalist, fda_reviewer, dea_officer) supported; two dissented. The resolve date has been corrected to 2026-09-30 to match the materially identical prediction 1 and avoid an artificial early resolution on 2026-06-01 that would not capture the full Q3 window. Confidence set at 0.78, reflecting the multi-agent consensus but acknowledging that an unexpected MDMA resubmission acceptance before June could shift sentiment even without final approval.